AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that the its novel clinical candidate drug ACD440 for peripheral neuropathic pain, is based on the seminal discoveries of TRPV1 by Prof.
October 6, 2021
· 5 min read